Moreover, as active NSPs have been found in the lung of COVID-19 patients with ARDS, the use of NSP inhibitors, such as α1-antitrypsin (α1AT), has been proposed in COVID-19 patients and particularly in patients with cystic fibrosis or α1AT deficiency (33–36). Here, SERPINA1 is linked to acute respiratory distress syndrome.